Today: 9 June 2026
Circle (CRCL) stock steadies near $87 after earnings pop as rate, regulation loom
27 February 2026
2 mins read

Circle (CRCL) stock steadies near $87 after earnings pop as rate, regulation loom

New York, Feb 26, 2026, 17:59 ET — After-hours

  • Circle shares added around 5% Thursday, clinging to much of Wednesday’s jump.
  • USDC’s growth is on investors’ minds as they juggle changing expectations around U.S. interest rates.
  • A fresh U.S. stablecoin rule proposal just landed, stirring up an extra near-term catalyst.

Circle Internet Group (CIRL) closed out Thursday up roughly 5% at $87.26, not showing much movement in the after-hours session. The stablecoin issuer had surged the previous day, putting it back in focus for traders.

The reason this matters: Circle’s business is straightforward and fully visible—it brings in interest from reserves held to support USDC, the stablecoin pegged to the dollar. CEO Jeremy Allaire called possible Fed rate cuts “welcome,” saying lower rates boost money “velocity.” For Seaport Research Partners’ Jeff Cantwell, the “key takeaway” is USDC is scaling “rapidly” regardless of the rate environment. Reuters

Circle reported a 72% jump in USDC in circulation, reaching $75.3 billion, which pushed fourth-quarter revenue and reserve income up by 77% to $770 million. Reserve income alone hit $733 million. The company is projecting 40% compound annual growth for USDC in circulation over the cycle, and expects “other revenue” between $150 million and $170 million in 2026. Circle calculates “revenue less distribution costs” as income net of fees paid to partners distributing USDC. Q4 Investor Relations

Shares jumped 35.5% Wednesday, their biggest gain since the company’s June 2025 IPO, according to MarketWatch. Crypto as a whole remained weak—bitcoin is off roughly 21% so far this year.

Circle highlighted recent product launches and new partnerships, moves the company says are aimed at diversifying revenue streams past just interest earned on reserves. Since launch, the Arc blockchain testnet has handled over 166 million transactions, according to the company, while the Circle Payments Network counted 55 financial institutions participating as of Feb. 20. CEO Allaire described the latest quarter as “another step forward” in the push for “an open, programmable internet financial system.” Circle

Wall Street analysts are reacting to the stock’s shifting rate exposure with revised targets. Needham slashed its price target to $130 from $190, pointing to softer interest rate projections and pressure from a slumping crypto market. Morgan Stanley, on the other hand, bumped its target up to $80 from $66. H.C. Wainwright stuck to a Neutral rating, saying it’s holding out for more insight into the Fed’s 2026 rate plans.

This trade comes with no shortage of pitfalls. Circle’s expenses to keep partners on board climbed as it ramped up distribution. And the stablecoin field is jammed, with Tether’s USDT—still private—dominating the space. If USDC stalls or if pricing faces pressure, margins could get pinched fast.

Regulation remains a wild card. The Office of the Comptroller of the Currency wants feedback on a proposed rule covering sections of the GENIUS Act that target payment stablecoin issuers. The rule touches on reserves, risk management, supervision. Comments are due 60 days after the Federal Register publishes the proposal.

Heading into Friday and the coming week, investors are tracking USDC circulation against shifting rate expectations. They’re also looking for more insight from Circle’s upcoming filings—think costs, reserve allocations, and when Arc mainnet might debut.

Stock Market Today

  • National Stock Exchange of India to Allocate 10% of CSR Funds to NSE Social Stock Exchange Projects
    June 9, 2026, 10:09 AM EDT. The National Stock Exchange of India (NSE) will earmark 10% of its annual Corporate Social Responsibility (CSR) corpus for deployment through projects listed on the NSE Social Stock Exchange (SSE). This move aims to channel corporate funds into social enterprises and initiatives that meet NSE SSE criteria, enhancing transparency and impact measurement. The NSE Social Stock Exchange, launched as a platform to support social ventures, allows investors and corporations to fund causes aligned with social development goals. This allocation underscores NSE's commitment to social responsibility and innovative financing for social impact projects.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Intel stock slides as chip rally cools — what’s driving INTC today
Previous Story

Intel stock slides as chip rally cools — what’s driving INTC today

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal
Next Story

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

Go toTop